Tirzepatide and smoking cessation: what we know so far

Step 1, understand what tirzepatide actually does in the brain

Tirzepatide is a dual GIP and GLP-1 receptor agonist, which means it activates two gut-hormone receptors simultaneously. Most people know GLP-1 medicines for slowing gastric emptying and reducing hunger, but GLP-1 receptors are also expressed in areas of the brain involved in reward and reinforcement, the same circuitry that underpins addictive behaviour. This is the mechanistic thread researchers are pulling on. Early preclinical data suggest GLP-1 receptor activation can reduce dopamine-driven reward responses to substances including nicotine and alcohol. GIP receptor involvement adds another variable that is less well characterised at this stage.

The NHS patient page for tirzepatide covers its licensed uses clearly: weight management alongside diet and activity changes, and type 2 diabetes. Smoking cessation does not appear because no regulator has assessed that indication. The biology is plausible; the clinical evidence needed to support a licence has not yet been gathered in completed trials at scale.

For a thorough overview of the medicine itself, including how the tirzepatide l formulation fits into the broader treatment range, the tirzepatide treatment page explains how it works, who it is licensed for, and what the SURMOUNT trial programme found.

Step 2, look at what patients and clinicians are actually reporting

The anecdotal signal is consistent enough that it has attracted serious attention. Clinicians treating patients with GLP-1 and dual-agonist medicines report that a meaningful number of them spontaneously mention reduced cravings for cigarettes, alcohol or ultra-processed food, sometimes within the first few weeks of treatment. A question our prescribers hear periodically is whether the pen is doing something beyond weight loss.

These observations are clinically interesting, but they sit well below the standard of evidence needed to recommend tirzepatide as a quit aid. Individual reports are subject to confounding: people who decide to improve their health often make several changes simultaneously. Reduced calorie intake, more activity, increased self-efficacy, all of these travel alongside starting a weight-loss medicine and all of them independently reduce smoking. Attributing a drop in cigarette consumption specifically to the drug requires a controlled trial design that has not yet been completed for tirzepatide.

Researchers exploring the relationship between Mounjaro and smoking behaviour are working within this gap between plausible mechanism and confirmed effect. Curiosity is warranted; certainty is not.

Step 3, place the evidence in context with what is known about GLP-1 medicines broadly

Semaglutide, the GLP-1 receptor agonist in Wegovy, has attracted similar interest and has more published data. Observational studies and some early trial data have suggested reduced smoking rates in people using GLP-1 medicines, though effect sizes and methodology vary considerably. Because tirzepatide adds GIP receptor activity to the mix, extrapolating semaglutide findings directly to tirzepatide is scientifically imprecise. The dual-agonist profile may strengthen the effect, weaken it, or produce a different pattern entirely, that is genuinely unknown.

NICE's appraisal of tirzepatide, published in December 2024, assessed the medicine for weight management in adults (TA1026) and made no findings on smoking. Any future indication would require a separate regulatory submission to the MHRA and, in all likelihood, a further NICE technology appraisal. That process typically takes several years from trial completion.

If you are considering tirzepatide primarily for weight management and you also smoke, that is exactly the kind of clinical picture worth raising at consultation. A prescriber can look at the whole picture, not just one variable.

Step 4, what to do if you want to stop smoking now

NHS Stop Smoking Services are free, evidence-based, and substantially more effective than going it alone. Combining behavioural support with licensed pharmacotherapy (varenicline, nicotine replacement, or bupropion) roughly triples the odds of quitting compared with willpower alone. These services do not require you to wait for a weight-loss medicine to arrive in the post; you can call your local service today.

If you are already on tirzepatide for weight management and notice your smoking urge reducing, that is worth mentioning to your prescriber at the next clinical review. Do not adjust your weight-loss dose or treatment plan in response to perceived smoking effects, any changes are a clinical decision. For context on what a typical treatment journey looks like, the guide to taking tirzepatide covers the titration schedule and what to expect month by month.

There is a separate question about cost that sometimes comes up here: people wonder whether starting a private weight-loss medicine alongside quit-smoking support is financially sensible. A plain overview of Mounjaro pricing in the UK sets out what private treatment typically involves, including what a legitimate transparent price actually covers. That context is worth reading before making any decision.

For the specific question of whether tirzepatide can directly help someone stop smoking, the honest answer in summer 2026 is: possibly, via its effects on reward pathways, but not yet proven. The question of whether Mounjaro helps you stop smoking is answered in more depth on a dedicated page, including the latest published research. If your primary goal is weight management and quitting happens to become easier alongside it, that would be welcome. Building a quit plan around it as the main mechanism would be premature.